Covid vaccines, because the government finances Irbm
The Minister of Economic Development, Giorgetti, has authorized an agreement with the Irbm group of Pomezia for an investment program of 34 million euros. All the details
The government invests 34 million euros in the Molecular Biology Research Institute (Irbm) of Pomezia for coronavirus vaccines.
Yesterday, the Minister of Economic Development, Giancarlo Giorgetti (Lega), authorized an agreement with the Irbm company to implement an investment program of 34 million euros, aimed at strengthening the capacity to fight Covid 19 and the spread of new coronaviruses . This was reported by a note from the Mise.
"With industrial and research and development projects – explains the note – the aim is to expand the capacity of the laboratories of two companies of the group, Irbm Spa and Advent Srl, increasing the production and testing of new vaccines and innovative therapies, also based on of the synergies created within the collaboration plan launched in 2020 with Oxford University and AstraZeneca ”.
The Roman company headed by Piero di Lorenzo has in fact worked in the production of the anti Covid-19 vaccine on behalf of Astrazeneca . And he was already on the hunt for funding.
As Startmag reported in January 2021: "Piero Di Lorenzo had hoped for an entry or intervention in the company of public entities, probing Cassa Depositi Prestiti (controlled by the Ministry of Economy), European Investment Bank (EIB) and Higher Institute of health care (Iss). "
And this funding has now arrived.
At the end of April, the European Investment Bank (EIB) also decided to finance with resources equal to 15 million euros led Irbm to fight the coronavirus and other infectious diseases.
All the details.
RESOURCES FROM MISE
The Ministry of Economic Development will facilitate the investment with 13 million euros. In addition, the government investment, in addition to safeguarding existing employment, will allow for the creation of over 50 new jobs. "It is the will of the government to continue to support investments in a strategic sector such as pharmaceuticals, where the ability to look to the future and prevent health crises becomes fundamental to guarantee the health of citizens and to cope with economic and social consequences", commented Minister Giancarlo Giorgetti.
"In this direction – continues the minister – goes the choice made to introduce, through a decree law, a new fast track mechanism to encourage business investments in our country and thus avoid losing significant opportunities due to long bureaucracy" .
WHAT IS IRBM
The company based in Pomezia, operating in the sector of molecular biotechnology, biomedical science and organic chemistry, has 200 employees.
As stated in the group's 2020 financial report, “Irbm was founded in 2010 as a spinoff of the pharmaceutical multinational Merck & Co and 2020 marked the tenth year as an independent research organization”.
Irbm Spa is the parent company of the companies of the Irbm group which includes the research institute in drug discovery Irbm and Advent Srl, a company that operates entirely in the field of applied research and experimental development and production in the sector of innovative vaccines based on recombined vectors. .
THE PARTNERS
With a share capital of 5 million euros, the company is controlled 98% by Ilaria di Lorenzo (co-founder and vice president) and 2% by Matteo Francesco Liguori.
THE GOVERNANCE
ALL THE NUMBERS OF THE IRBM GROUP 2020
THE COLLABORATION WITH THE JENNER INSTITUTE FOR THE ASTRAZENCA VACCINE
The Roman company collaborated with the Jenner Institute of the University of Oxford to develop the Covid vaccine produced by Astrazeneca. As La Verità points out, "Irbm continues to have good connections with AstraZeneca which no longer has a contract with Europe on its vaccine and which is now focusing on the development of a monoclonal antibody for the prevention of patients who fail to develop antibodies. after the first doses of the vaccine ".
"The Italian institute chaired by Piero Di Lorenzo and which collaborates with AstraZeneca in the control tests on the anti Covid vaccine has recently been redeemed by the EMA from the accusation of causing deaths from thromboembolism" reports the Corriere della Sera .
THE MERCK-IRBM PARTNERSHIP
Finally, the Italian company, leader in the production of viral vectors, also has an active collaboration with the pharmaceutical giant Merck. The two companies, as announced in 2020 on the Irbm website , are working on "a new anti Covid drug in aerosol or injectable formulation, using a valid platform for adaptation to emerging variants".
This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/sanita/vaccini-anti-covid-perche-il-governo-finanzia-irbm/ on Wed, 11 May 2022 13:27:12 +0000.